Publications

Genome medicine

The contribution of rare germline variants to the immune landscape of breast cancer.

09-05-2026

The American journal of surgical pathology

Performance Assessment of a Deep Learning-based Algorithm for Ovarian Cancer Histotyping in an Independent Data Set.

01-02-2026

NPJ digital medicine

H&E to IHC virtual staining methods in breast cancer: an overview and benchmarking.

02-07-2025

iScience

Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial.

16-08-2024

British journal of cancer

Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1).

01-08-2024

NPJ breast cancer

Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade.

18-04-2024

Cancer cell

CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1.

09-10-2023

Nature communications

Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.

07-02-2023

Cancers

Homologous Recombination Deficiency and Cyclin E1 Amplification Are Correlated with Immune Cell Infiltration and Survival in High-Grade Serous Ovarian Cancer.

02-12-2022

NPJ breast cancer

Deep learning for fully-automated nuclear pleomorphism scoring in breast cancer.

08-11-2022

International journal of cancer

Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial.

15-10-2022

Cancers

External Quality Assessment 2.0: The Importance of a Standardized Implementation of TILs for Daily and Trial Practices.

02-08-2022

NPJ breast cancer

Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancer.

28-04-2022

Cancer treatment reviews

Erratum to "Prognostic factors in patients with oligometastatic breast cancer - A systematic review". [Cancer treatment Rev. 91 (2020) 102114].

01-01-2021

Virchows Archiv : an international journal of pathology

The effect of the peritoneal tumor microenvironment on invasion of peritoneal metastases of high-grade serous ovarian cancer and the impact of NEOADJUVANT chemotherapy.

01-10-2020

Nature communications

Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.

07-08-2020

Molecular cancer research : MCR

The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor-Positive Breast Cancers.

01-07-2020

Oncoimmunology

Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival.

14-12-2018

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type.

01-11-2009

Breast cancer research and treatment

Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH.

01-08-2009

Cancer cell

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

01-10-2007

Experimental lung research

Lung tumor location and lymphocyte infiltration in mice are genetically determined.

01-06-2005

The contribution of rare germline variants to the immune landscape of breast cancer.

Performance Assessment of a Deep Learning-based Algorithm for Ovarian Cancer Histotyping in an Independent Data Set.

H&E to IHC virtual staining methods in breast cancer: an overview and benchmarking.

Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial.

Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1).

Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade.

CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1.

Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.

Homologous Recombination Deficiency and Cyclin E1 Amplification Are Correlated with Immune Cell Infiltration and Survival in High-Grade Serous Ovarian Cancer.

Deep learning for fully-automated nuclear pleomorphism scoring in breast cancer.

Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial.

External Quality Assessment 2.0: The Importance of a Standardized Implementation of TILs for Daily and Trial Practices.

Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancer.

Erratum to "Prognostic factors in patients with oligometastatic breast cancer - A systematic review". [Cancer treatment Rev. 91 (2020) 102114].

The effect of the peritoneal tumor microenvironment on invasion of peritoneal metastases of high-grade serous ovarian cancer and the impact of NEOADJUVANT chemotherapy.

Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.

The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor-Positive Breast Cancers.

Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival.

Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type.

Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH.

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Lung tumor location and lymphocyte infiltration in mice are genetically determined.

This site uses cookies